Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase II drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tonabersat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tonabersat overview
Tonabersat (HCB-1019) is under development for the treatment of diabetic macular edema (DME), diabetic nephropathy (DR), dry and wet age-related macular degeneration (AMD) and geographic atrophy. It is administered through oral route in the form of tablet. It acts by targeting connexin 43 (Cx43) and NLRP3.
Inflammx Therapeutics overview
Inflammx Therapeutics is a provider of a biotechnology services. Inflammx Therapeutics is headquartered in Tampa, Florida, the US.
For a complete picture of Tonabersat’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.